Risk of Funding Requirements for Research and Development Exceeding Expectations
First written in FY2017. 16 of 28 entries say "Worsened", first in FY2019-Q2. Latest entry: 2026-08-07.
OncoTherapy Science moved to the "Worse" side of this theme in 2020, 1 year before the typical company in this theme (2021).
The whole theme swung hardest in 2019: 4 of 13 companies on the "Worse" side.
2 other companies' latest entry also says "Mitigated".
- 2026-08-07MitigatedEarnings
「As of the end of the first-quarter consolidated accounting period, the Company held cash and deposits of ¥2,326 million and determined that there was no concern regarding the continuity of its business activities for the foreseeable future and that no material uncertainty related to the going-concern assumption was recognized.」
Cash and deposits increased from ¥2,089 million at the end of March 2026 to ¥2,326 million, further improving the Company's capacity to fund research and development. - FY2026MitigatedAnnual report
「Cash and cash equivalents for the consolidated fiscal year amounted to ¥2,089 million, an increase of ¥1,255 million from the previous consolidated fiscal year.」
Cash and cash equivalents increased from ¥833 million at the end of the previous fiscal year to ¥2,089 million, mainly due to financing through the issuance of shares. The risk of funding pressure from front-loaded research and development expenses remains, but cash on hand improved. - 2026-05-08MitigatedRevision of earnings forecasts
「Cash and cash equivalents (hereinafter, "funds") at the end of the fiscal year amounted to ¥2,089 million, an increase of ¥1,255 million from the previous consolidated fiscal year.」
Cash and cash equivalents increased from ¥833 million at the end of the previous fiscal year to ¥2,089 million, mainly due to funding through the issuance of shares, improving the Company's capacity to fund research and development. - FY2026-H1MitigatedAnnual report
「As of the end of the interim consolidated accounting period, the Group held ¥1,675 million in cash and deposits, and there are no concerns about the continuity of business activities for the foreseeable future,」
Cash and deposits increased from ¥833 million at the end of the previous fiscal year to ¥1,675 million. Although the number of years of research and development expenses covered by these funds has not been indicated, cash on hand improved through financing by issuing shares. - FY2025MitigatedAnnual report
「Cash and cash equivalents for the consolidated fiscal year amounted to ¥833 million, an increase of ¥306 million from the previous consolidated fiscal year.」
Cash and cash equivalents increased from ¥527 million at the end of the previous fiscal year to ¥833 million, mainly due to financing through the issuance of shares. Although constraints on research and development funding remain, cash on hand has improved. - FY2025-H1MitigatedAnnual report
「Cash and cash equivalents at the end of the interim consolidated accounting period were ¥1,098 million. In addition, cash flow from financing activities increased funds by ¥1,149 million, mainly due to ¥1,174 million in proceeds from the issuance of shares.」
Cash and cash equivalents increased from ¥527 million at the end of FY2024 to ¥1,098 million, and funding through the issuance of shares also progressed. Constraints on the funding available for research and development remain, but the company reported an increase in cash on hand from financing during the interim period. - FY2024WorsenedAnnual report
「Cash and cash equivalents at the end of the consolidated fiscal year were ¥527 million.」
Cash and cash equivalents declined from ¥1,117 million at the end of the previous consolidated fiscal year to ¥527 million. The previous explanation of how many years' worth of research and development expenses had been secured was also absent, and constraints on the funding available for research and development remain. - FY2024-Q3WorsenedAnnual report
「As of the end of the third quarter of the consolidated fiscal period, we held ¥881 million in cash and deposits, and will conduct research and development in line with the status of funding,」
Cash and deposits declined from ¥912 million at the end of the previous quarter to ¥881 million, and the explanation that research and development would be conducted in line with the status of funding remained in place. The constraint on the funding available for research and development has tightened. - FY2024-Q2WorsenedAnnual report
「As of the end of the second quarter of the consolidated fiscal period, we held ¥881 million in cash and deposits, and will conduct research and development in line with the status of funding,」
Cash and deposits declined from ¥912 million in FY2024-Q1 to ¥881 million. The explanation that research and development would be conducted in line with the status of funding remained in place, indicating a tighter constraint on the funding available for research and development. - FY2024-Q1WorsenedAnnual report
「As of the end of the first quarter of the consolidated fiscal period, we held ¥912 million in cash and deposits, and will conduct research and development in line with the status of funding,」
Cash and deposits declined from ¥1,117 million at the end of March 2023 to ¥912 million. The previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was absent, and the company stated that research and development would be conducted in line with the status of funding. - FY2023WorsenedAnnual report
「As of the end of the consolidated fiscal year, we held ¥1,117 million in cash and deposits. In addition, with respect to the issuance of new shares through a third-party allotment, and the 34th and 35th stock acquisition rights, with Long Corridor Alpha Opportunities Master Fund and MAP246 Segregated Portfolio as the allottees, as resolved by the Company's Board of Directors on 24 March 2023, payment of the total issue proceeds (LCAO: ¥76,760 thousand; MAP246: ¥19,190 thousand) was completed on 10 April 2023.」
Cash and deposits at the end of the fiscal year were ¥1,117 million, down from ¥1,836 million at the end of the previous fiscal year. The previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was absent, and the description of the funding cushion remains weak. Meanwhile, the filing states that funds were received after submission through a third-party allotment. - FY2023-Q3WorsenedAnnual report
「As of the end of the third quarter of the consolidated fiscal period, we held ¥977 million in cash and deposits. We therefore determined that there was no concern about the continuity of business activities for the time being and that no material uncertainty existed regarding the going concern assumption.」
Cash and deposits declined from ¥1,313 million at the end of the previous quarter to ¥977 million. The previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was also absent, and the description of the funding cushion remains weak. - FY2023-Q2WorsenedAnnual report
「As of the end of the second quarter of the consolidated fiscal period, we held ¥1,313 million in cash and deposits. We therefore determined that there was no concern about the continuity of business activities for the time being and that no material uncertainty existed regarding the going concern assumption.」
Cash and deposits declined from ¥1,505 million at the end of the previous quarter to ¥1,313 million. The previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was absent, and the description of the funding cushion for research and development remains weak. - FY2023-Q1WorsenedAnnual report
「As of the end of the first quarter of the consolidated fiscal period, we held ¥1,505 million in cash and deposits. We therefore determined that there was no concern about the continuity of business activities for the time being and that no material uncertainty existed regarding the going concern assumption.」
Cash and deposits declined from ¥1,836 million at the end of the previous consolidated fiscal year to ¥1,505 million. The previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was absent, and the description of the funding cushion for research and development remains weak. - FY2022WorsenedAnnual report
「As of the end of the consolidated fiscal year, we held ¥1,836 million in cash and deposits. In addition, by implementing the measures described below, there was no concern about the continuity of business activities for the time being,」
Cash and deposits declined from ¥2,899 million at the end of the previous consolidated fiscal year to ¥1,836 million. The previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was also absent, and the description of the funding cushion for research and development has weakened further. - FY2022-Q3WorsenedAnnual report
「As of the end of the third quarter of the consolidated fiscal period, we held ¥2,221 million in cash and deposits. In addition, by implementing the measures described below, there was no concern about the continuity of business activities for the time being,」
Cash and deposits declined from ¥3,122 million at the end of the previous quarter to ¥2,221 million, and the previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was also absent. The description of the funding cushion for research and development has weakened further. - FY2022-Q2WorsenedAnnual report
「As of the end of the second quarter of the consolidated fiscal period, we held ¥3,122 million in cash and deposits. We therefore determined that there was no concern about the continuity of business activities for the time being and that no material uncertainty existed regarding the going concern assumption.」
Cash and deposits declined from ¥3,136 million at the end of the previous quarter to ¥3,122 million. The determination that no material uncertainty existed regarding the going concern assumption remained in place, but the previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was still absent. - FY2022-Q1WorsenedAnnual report
「As of the end of the first quarter of the consolidated fiscal period, we held ¥3,136 million in cash and deposits. We therefore determined that there was no concern about the continuity of business activities for the time being and that no material uncertainty existed regarding the going concern assumption.」
Cash and deposits increased from ¥2,899 million at the end of the previous consolidated fiscal year to ¥3,136 million, but the previous explanation that approximately 1.5 years' worth of research and development expenses had been secured was removed. The description of the funding cushion for research and development has weakened. - FY2021-Q3WorsenedAnnual report
「As of the end of the third quarter of the consolidated fiscal period, we held ¥3,394 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so」
The period that could be covered by research and development expenses remained approximately 1.5 years, but cash and deposits declined from ¥3,729 million at the end of the previous quarter to ¥3,394 million. - FY2021-Q2WorsenedAnnual report
「As of the end of the second quarter of the consolidated fiscal period, we held ¥3,729 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so」
The period that could be covered by research and development expenses remained approximately 1.5 years, but cash and deposits declined from ¥4,160 million at the end of the previous quarter to ¥3,729 million. - FY2021-Q1WorsenedAnnual report
「As of the end of the first quarter of the consolidated fiscal period, we held ¥4,160 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so」
The period that could be covered by research and development expenses remained approximately 1.5 years, but cash and deposits declined from ¥4,713 million at the end of the previous consolidated fiscal year to ¥4,160 million. - FY2020-Q3RestatedAnnual report
「As of the end of the third quarter of the consolidated fiscal period, we held ¥4,470 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so」
The company held ¥4,470 million in cash and deposits and continued to state that it had secured approximately 1.5 years' worth of research and development expenses. - FY2020-Q2RestatedAnnual report
「As of the end of the second quarter of the consolidated fiscal period, we held ¥4,530 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so」
Cash and deposits declined from ¥4,632 million at the end of the previous quarter, but the explanation that approximately 1.5 years' worth of research and development expenses had been secured remained in place. - FY2020-Q1RestatedAnnual report
「As of the end of the first quarter of the consolidated fiscal period, we held ¥4,632 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so」
Cash and deposits declined from ¥4,857 million at the end of the previous consolidated fiscal year to ¥4,632 million, but the explanation that approximately 1.5 years' worth of research and development expenses had been secured remained in place. - FY2019-Q3RestatedAnnual report
「As of the end of the third quarter of the consolidated fiscal period, we held ¥4,877 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so there was no concern about the continuity of business activities for the time being,」
Cash and deposits declined from ¥5,339 million at the end of the previous quarter to ¥4,877 million, but the explanation that approximately 1.5 years' worth of research and development expenses had been secured remained in place. - FY2019-Q2WorsenedAnnual report
「As of the end of the second quarter of the consolidated fiscal period, we held ¥5,339 million in cash and deposits and had secured approximately 1.5 years' worth of research and development expenses, so there was no concern about the continuity of business activities for the time being,」
The period that could be covered by research and development expenses has shortened from approximately two years previously to approximately 1.5 years. The description of the funding cushion against the risk of research and development funding exceeding assumptions has weakened. - FY2018RestatedAnnual report
「As of the end of the fiscal year, we held ¥6,740 million in cash and deposits and had secured approximately two years' worth of research and development expenses, so there was no concern about the continuity of business activities for the time being,」
The risk that research and development funding will exceed assumptions remains, but an explanation has been added that the company holds ¥6,740 million in cash and deposits, enough to cover approximately two years of research and development expenses. - FY2017First statedAnnual report
「Due to the nature of the Group's business, substantial funding, including funding for research and development, is required. However, as the environment changes with rapid growth, technological change and market development, the funding required to implement new strategies and develop the business may increase beyond current assumptions.」
The risk that funding required for research and development and the implementation of new strategies may exceed current assumptions has been disclosed.